CE Mark Approval for Biolimus A9™ Coated Cobalt Chromium Coronary Stent System BioFreedom™ Ultra
October 19, 2020 | News | BioFreedom™ Ultra
BioFreedom™ Ultra is Biosensors International new, novel thin strut CoCr polymer and carrier-free Drug Coated Stent with Biosensors proprietary limus BA9™, a highly lipophilic anti-restenotic drug, developed specifically for use in coronary vascular applications. BioFreedom™ Ultra successfully extends the LEADERS FREE legacy in LEADERS FREE III.
OUTSTANDING TWO-YEAR RESULTS FROM THE BioMatrix™ ALPHA REGISTRY
October 14, 2020 | News | BioMatrix Alpha
At TCT CONNECT Dr Ian Menown's presentation of
excellent 2-year follow-up results.
1% def/prob ST, 1% Cardiac Death and 3% MI.
ALPHA BY DESIGN
The 1st DCS/DES approved with 1 month DAPT in High Bleeding Risk patients
December 3, 2020 | News | BioFreedom™ Family
BioFreedom™ since 2015 (CE marked) and now
BioFreedom™ ULTRA is available in CoCr.
The primary endpoint of LEADERS FREE III was presented at PCR e-course 2020
June 27,2020 | News | BioFreedom™ Ultra
The study evaluates the safety and efficacy of the novel thin-strut (84µm) CoCr polymer-free DCS BioFreedom™ Ultra in HBR patients. Details are available in Professor Eberli’s presentation.
Blue Sail / Biosensors Intl. enters the Structural Heart business and welcomes NVT into the group
June 9,2020 | News | Corporate information
Biosensors International, part of Blue Sail Medical, announced today the completion of its acquisition of
NVT AG, Muri (Argau, Switzerland), which was previously communicated on September 20, 2019.
BIOSENSORS INTERNATIONAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN NEW PIVOTAL DRUG COATED BALLOON TRIAL "REFORM".
August 11, 2020 | News | Drug-eluting Balloons
The REFORM trial, utilises a Biolimus A9™ coated balloon, the latest development in Biosensors International balloon technology.